Cagrilintide
Cagrilintide
Overview
Cagrilintide is a long-acting synthetic amylin analog developed by Novo Nordisk that is currently in Phase 3 clinical trials in combination with semaglutide (the combination called CagriSema) for obesity treatment. Early trial data has shown average weight loss of 22% of body weight — approaching the efficacy of bariatric surgery — making it one of the most anticipated metabolic peptide therapeutics in development. Cagrilintide represents the next generation of anti-obesity pharmacotherapy combining amylin receptor agonism with GLP-1 receptor agonism for enhanced efficacy.
Mechanism of Action
Cagrilintide is a fatty-acid modified amylin analog with a half-life of approximately one week enabling once-weekly dosing. It acts through amylin receptors in the hypothalamus and brainstem producing satiety signaling that complements GLP-1 receptor agonism through distinct but synergistic pathways. Amylin receptor activation reduces meal size through direct satiety center effects while GLP-1 receptor activation slows gastric emptying and reduces appetite through separate hypothalamic circuits. The combination produces greater weight loss than either mechanism alone because the two pathways converge on food intake regulation without complete overlap. In Phase 3 trials the CagriSema combination (cagrilintide 2.4mg + semaglutide 2.4mg weekly) has demonstrated 22-25% mean weight loss at 68 weeks.
Dosage Information
Typical Dose
0.3-2.4 mg weekly (Phase 3 trial doses)
Frequency
Once weekly
Administration
Subcutaneous injection
Notes
Not yet FDA approved — currently in Phase 3 trials. This entry documents the research context. Commercial availability expected 2025-2026 pending regulatory approval.
Where does Cagrilintide sit?
See how this peptide compares across all 111 peptides in our database.
Evidence Score
0.74
Compound Data
Molecular Formula
C194H312N54O59S2
Molecular Weight
4409.00 g/mol
IUPAC Name
20-[[(1S)-4-[[(2S)-6-amino-1-[[(4R,7S,10S,13S,16S,19R)-4-[[(2S)-1-[[(2S,3R)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2R)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S)-1-[[2-[(2S)-2-[[(2S,3S)-1-[[(2R)-1-[(2R)-2-[(2R)-2-[[(2R,3S)-1-[[(2R)-4-amino-1-[[(2R)-1-[[2-[[(2R)-1-[[(2R)-4-amino-1-[[(2R,3S)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]carbamoyl]-16-(2-amino-2-oxoethyl)-7,13-bis[(1R)-1-hydroxyethyl]-10-methyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxohexan-2-yl]amino]-1-carboxy-4-oxobutyl]amino]-20-oxoicosanoic acid
PubChem CID
171397054Potential Side Effects
Community Experiences
No experiences shared yet. Be the first!
Quick Facts
- Administration
- Subcutaneous injection
- Typical Dose
- 0.3-2.4 mg weekly (Phase 3 trial doses)
- Frequency
- Once weekly
- References
- 0 curated + 42 from PubMed
- Clinical Trials
- 32 registered
- Evidence Score
- 0.7 / 100